Results 111 to 120 of about 149 (148)

Association of baseline and longitudinal changes in insulin‐like growth factor‐binding protein‐7 with the risk of incident heart failure: Data from the PREVEND study

open access: yesEuropean Journal of Heart Failure, EarlyView.
Insulin‐like growth factor‐binding protein‐7 (IGFBP7) and heart failure (HF) risk: the PREVEND study. CI, confidence interval; HR, hazard ratio. Abstract Aim Senescence is a major risk factor for heart failure (HF), and insulin‐like growth factor‐binding protein‐7 (IGFBP7) has been identified as an important senescence‐inducing factor.
Sabrina Abou Kamar   +9 more
wiley   +1 more source

Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology

open access: yesEuropean Journal of Heart Failure, EarlyView.
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a ...
Maurizio Volterrani   +21 more
wiley   +1 more source

The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis

open access: yesEuropean Journal of Heart Failure, EarlyView.
Proposed algorithm to screen for transthyretin cardiac amyloidosis (ATTR‐CA). AL‐CA, immunoglobulin light‐chain cardiac amyloidosis; AMYLI, AMYLoidosis Index; AUC, area under the curve; IWT, increased wall thickness; LVEF, left ventricular ejection fraction; PYP, pyrophosphate.
Giovanni Battista Bonfioli   +11 more
wiley   +1 more source

New cardiovascular biomarkers in patients with advanced cancer – A prospective study comparing MR‐proADM, MR‐proANP, copeptin, high‐sensitivity troponin T and NT‐proBNP

open access: yesEuropean Journal of Heart Failure, EarlyView.
(A) Univariable receiver operating characteristic (ROC) curves for all biomarkers. (B) Kaplan–Meier curves for best cut‐point of mid‐regional pro‐adrenomedullin (MR‐proADM) for survival (n = 442). AUC, area under the curve; CI, confidence interval; HR, hazard ratio; hsTnT, high‐sensitivity troponin T; MR‐proANP, mid‐regional pro‐atrial natriuretic ...
Markus S. Anker   +18 more
wiley   +1 more source

Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts

open access: yesEuropean Journal of Heart Failure, EarlyView.
Markers of progression to heart failure (HF). Gal‐4, galectin‐4; GDF‐15, growth differentiation factor 15; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; ST2, suppression of tumorigenicity‐2. ABSTRACT Aims Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart ...
Anna Dieden   +23 more
wiley   +1 more source

Insights into the interconnection of sarcopenia in heart failure

open access: yes
ESC Heart Failure, EarlyView.
Zhengyang Ge, Yanming Wu, Biao Wang
wiley   +1 more source

Relevance of residual tricuspid regurgitation for right ventricular reverse remodelling after tricuspid valve intervention in patients with severe tricuspid regurgitation and right‐sided heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
Right ventricular reverse remodelling after transcatheter tricuspid valve intervention (TTVI). Optimal tricuspid regurgitation (TR) reduction is critical for right ventricular reverse remodelling. CMR, cardiac magnetic resonance; echo, echocardiography; RV EDV, right ventricular end‐diastolic volume. Abstract Aims Right ventricular reverse remodelling (
Ludwig T. Weckbach   +16 more
wiley   +1 more source

Current and novel biomarkers in cardiogenic shock

open access: yesEuropean Journal of Heart Failure, EarlyView.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko   +5 more
wiley   +1 more source

C-type natriuretic peptide in childhood obesity

Peptides, 2021
According to the World Health Organization obesity is the result of an energy imbalance between calories assumed and expended and over the past 30 years its incidence has dramatically increased. Recently, the problem of obesity has drastically increased also in childhood, assuming a social relevance.
Manuela Cabiati   +3 more
openaire   +2 more sources

C-Type Natriuretic Peptide

Peptides, 1996
C-type natriuretic peptide is a 22-amino acid peptide that was initially identified in the central nervous system. The distribution of C-type natriuretic peptide, which has structural homology with atrial and brain natriuretic peptides, is wide and includes the endothelium, myocardium, gastrointestinal, and genitourinary tracts.
Barr, Craig S.   +2 more
openaire   +6 more sources

Home - About - Disclaimer - Privacy